Literature DB >> 26032550

Prostate cancer: Cabazitaxel-a key therapeutic option in prostate cancer.

Anuradha Jayaram1, Gerhardt Attard1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26032550     DOI： 10.1038/nrurol.2015.98

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  10 in total

1.  Enzalutamide in metastatic prostate cancer before chemotherapy.

Authors:  Tomasz M Beer; Bertrand Tombal
Journal:  N Engl J Med       Date:  2014-10-30       Impact factor: 91.245

2.  Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279).

Authors:  Amit Bahl; Susan Masson; Zafar Malik; Alison J Birtle; Santhanam Sundar; Rob J Jones; Nicholas D James; Malcolm D Mason; Satish Kumar; David Bottomley; Anna Lydon; Simon Chowdhury; James Wylie; Johann S de Bono
Journal:  BJU Int       Date:  2015-06-16       Impact factor: 5.588

3.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

Authors:  Johann Sebastian de Bono; Stephane Oudard; Mustafa Ozguroglu; Steinbjørn Hansen; Jean-Pascal Machiels; Ivo Kocak; Gwenaëlle Gravis; Istvan Bodrogi; Mary J Mackenzie; Liji Shen; Martin Roessner; Sunil Gupta; A Oliver Sartor
Journal:  Lancet       Date:  2010-10-02       Impact factor: 79.321

4.  Novel actions of next-generation taxanes benefit advanced stages of prostate cancer.

Authors:  Renée de Leeuw; Lisa D Berman-Booty; Matthew J Schiewer; Stephen J Ciment; Robert B Den; Adam P Dicker; William K Kelly; Edouard J Trabulsi; Costas D Lallas; Leonard G Gomella; Karen E Knudsen
Journal:  Clin Cancer Res       Date:  2015-02-15       Impact factor: 12.531

5.  Abiraterone in metastatic prostate cancer without previous chemotherapy.

Authors:  Charles J Ryan; Matthew R Smith; Johann S de Bono; Arturo Molina; Christopher J Logothetis; Paul de Souza; Karim Fizazi; Paul Mainwaring; Josep M Piulats; Siobhan Ng; Joan Carles; Peter F A Mulders; Ethan Basch; Eric J Small; Fred Saad; Dirk Schrijvers; Hendrik Van Poppel; Som D Mukherjee; Henrik Suttmann; Winald R Gerritsen; Thomas W Flaig; Daniel J George; Evan Y Yu; Eleni Efstathiou; Allan Pantuck; Eric Winquist; Celestia S Higano; Mary-Ellen Taplin; Youn Park; Thian Kheoh; Thomas Griffin; Howard I Scher; Dana E Rathkopf
Journal:  N Engl J Med       Date:  2012-12-10       Impact factor: 91.245

6.  Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents.

Authors:  Carmel J Pezaro; Aurelius G Omlin; Amelia Altavilla; David Lorente; Roberta Ferraldeschi; Diletta Bianchini; David Dearnaley; Christopher Parker; Johann S de Bono; Gerhardt Attard
Journal:  Eur Urol       Date:  2013-12-17       Impact factor: 20.096

7.  Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone.

Authors:  D Bianchini; D Lorente; A Rodriguez-Vida; A Omlin; C Pezaro; R Ferraldeschi; A Zivi; G Attard; S Chowdhury; J S de Bono
Journal:  Eur J Cancer       Date:  2013-09-25       Impact factor: 9.162

8.  Patient-reported outcome labeling claims and measurement approach for metastatic castration-resistant prostate cancer treatments in the United States and European Union.

Authors:  Marci J Clark; Nimanee Harris; Ingolf Griebsch; Dagmar Kaschinski; Catherine Copley-Merriman
Journal:  Health Qual Life Outcomes       Date:  2014-07-04       Impact factor: 3.186

9.  Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms.

Authors:  Aurelius Omlin; Carmel Pezaro; Deborah Mukherji; Amy Mulick Cassidy; Shahneen Sandhu; Diletta Bianchini; David Olmos; Roberta Ferraldeschi; Gal Maier; Emilda Thompson; Chris Parker; Gerhardt Attard; Johann de Bono
Journal:  Eur Urol       Date:  2013-01-04       Impact factor: 20.096

10.  Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100).

Authors:  Y Loriot; D Bianchini; E Ileana; S Sandhu; A Patrikidou; C Pezaro; L Albiges; G Attard; K Fizazi; J S De Bono; C Massard
Journal:  Ann Oncol       Date:  2013-04-10       Impact factor: 32.976
  10 in total
  1 in total

1.  Jungermannenone A and B induce ROS- and cell cycle-dependent apoptosis in prostate cancer cells in vitro.

Authors:  Yan-Xia Guo; Zhao-Min Lin; Mei-Juan Wang; Yi-Wen Dong; Huan-Min Niu; Charles Yf Young; Hong-Xiang Lou; Hui-Qing Yuan
Journal:  Acta Pharmacol Sin       Date:  2016-05-02       Impact factor: 6.150
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.